Table 1

Summary of the SUSTAIN results9 10 16 20–26

Trial (n)	Background regimen†	Doses and comparators	Body weight change from baseline (kg)	Patients with weight loss of>5% (%)
SUSTAIN 1 (n=388)13	Diet and Exercise	SC semaglutide 0.5 mg	–3.73*	37*
		SC semaglutide 1.0 mg	–4.53*	45*
		Placebo	–0.98	7
SUSTAIN 2 (n=1231)8	Metformin, pioglitazone, rosiglitazone	SC semaglutide 0.5 mg	–4.3*	46*
		SC semaglutide 1.0 mg	–6.1*	62*
		Sitagliptin 100 mg	–1.9	18
SUSTAIN 3 (n=809)9	Metformin, Sulfonylurea, Thiazolidinedione	SC semaglutide 1.0 mg	–5.6*	52*
SUSTAIN 3 (n=809)9	Metformin, Sulfonylurea, Thiazolidinedione	Exenatide ER 2 mg	–1.9	17
SUSTAIN 4 (n=1089)15	Metformin, Sulfonylurea	SC semaglutide 0.5 mg	–3.47*	37*
		SC semaglutide 1.0 mg	–5.17*	51*
		Insulin glargine	1.15	5
SUSTAIN 5 (n=397)12	Metformin, Basal insulin	SC semaglutide 0.5 mg	–3.7*	42*
		SC semaglutide 1.0 mg	–6.4*	66*
		Placebo	–1.4	11
SUSTAIN 6 (n=3297)11	0–2 antihyperglycemic agents	SC semaglutide 0.5 mg	–3.6*	NR
		SC semaglutide 1.0 mg	–4.9*
		Placebo 1.0 mg	–0.7
		Placebo 0.5 mg	–0.5
SUSTAIN 7 (n=1201)16	Metformin	SC semaglutide 0.5 mg	–4.6*	44*
		Dulaglutide 0.75 mg	–2.3	23
		SC semaglutide 1.0 mg	–2.3*	63*
		Dulaglutide 1.5 mg	–1.1	30
SUSTAIN 8 (n=788)17	Metformin	SC semaglutide 1.0 mg	–5.3*	53
SUSTAIN 8 (n=788)17	Metformin	Canagliflozin 300 mg	–4.2	47
SUSTAIN 9 (n=302)14	Metformin, Sulfonylurea, SGLT-2 inhibitor	SC semaglutide 1.0 mg	–4.7*	50*
SUSTAIN 9 (n=302)14	Metformin, Sulfonylurea, SGLT-2 inhibitor	Placebo	–0.9	8
SUSTAIN 10 (n=577)18	Metformin, SGLT-2 inhibitor	SC semaglutide 1.0 mg	–5.8*	56*
SUSTAIN 10 (n=577)18	Metformin, SGLT-2 inhibitor	Liraglutide 1.2 mg	–1.9	18

*P<0.05 indicating the the superiority of semaglutide vs the respective comparator.
†Alone or in combination with one another.
ER, extended release; NR, not recorded; SC, subcutaneous; SGLT-2, sodium glucose cotransporter 2; SUSTAIN, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes.